Product Datasheet

Dacinostat

Catalog No. **BP-02512** · CAS **404951-53-7** · Form **free base** · Physical state **solid** · Color **Light yellow to yellow** · Version **1.0** · Revision **2026-09-10**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
HDAC; Autophagy	**Cancer**

Molecular formula	$C_{22}H_{25}N_3O_3$
Molecular weight	**379.4522**

STRUCTURE



DESCRIPTION

Dacinostat is a potent HDAC inhibitor, with an IC50 of 32 nM; Dacinostat also inhibits HDAC1 with an IC50 of 9 nM, and used in cancer research.

BIOLOGICAL ACTIVITY

LAQ824 (NVP-LAQ824) is a potent novel histone deacetylase (HDAC) inhibitor with an IC50 of 0.032 μM. NVP-LAQ824 also inhibited patient MM cell growth in a dose- and time-dependent manner. NVP-LAQ824-induced apoptotic signaling includes up-regulation of p21, caspase cascade activation, and poly (adenosine diphosphate [ADP]) ribose (PARP) cleavage.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1].Atadja P, et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004 Jan 15;64(2):689-95.

[2].Cho YS, et al. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824). J Med Chem. 2010 Apr 8;53(7):2952-63.

[3].Romanski A, et al. Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle. 2012 Sep 1;11(17):3219-26.